Evidence map›Paper›PMID 35024462›Full record

ArticleClinical and translational radiation oncology2022

Imaging response assessment for predicting outcomes after bioselection chemotherapy in larynx cancer: A secondary analysis of two prospective trials.

Laila A Gharzai, Julia Pakela, Elizabeth M Jaworski, Issam El Naqa, Jennifer Shah, Peter G Hawkins, Matthew E Spector, Carol R Bradford, Steven B Chinn, Kelly Malloy and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Laila A GharzaiDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.
Julia PakelaApplied Physics Program, University of Michigan, Ann Arbor, MI, United States.
Elizabeth M JaworskiDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.
Issam El NaqaApplied Physics Program, University of Michigan, Ann Arbor, MI, United States.
Jennifer ShahDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.
Peter G HawkinsDepartment of Radiation Oncology, The Kaiser Permanente Medical Group, Rohnert Park, CA, United States.
Matthew E SpectorDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Carol R BradfordDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Steven B ChinnDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Kelly MalloyDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Robbi KupferDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Andrew ShumanDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Robert MorrisonDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Chaz L StuckenDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Andrew RoskoDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Mark E PrinceDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Keith CasperDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Avraham EisbruchDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.
Gregory WolfDepartment of Otolaryngology, University of Michigan, Ann Arbor, MI, United States.
Paul L SwiecickiDepartment of Medical Oncology, University of Michigan, Ann Arbor, MI, United States.
Francis WordenDepartment of Medical Oncology, University of Michigan, Ann Arbor, MI, United States.
Michelle L MierzwaDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.
University of Michigan–Ann Arbor · USKaiser Permanente · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeBioselection with induction chemotherapy in larynx cancer is associated with excellent larynx preservation and disease-specific survival but requires visual inspection of the primary tumor. We retrospectively compare clinical and imaging response in bioselected patients to develop predictive models of surgeon-assessed response (SR), laryngectomy-free survival (LFS), and overall survival (OS) in bioselected patients. MATERIALS AND

methodsIn a secondary analysis of patients on two single-institution bioselection trials, model building used a regularized regression model (elastic-net) and applied nested cross-validation. Logistic regression-based model was used to predict SR and Cox proportional hazard-based models were used to predict LFS and OS.

resultsIn 115 patients with a median age of 57 years, most patients had supraglottic tumors (73.0%) and T3/T4 disease (94.8%). Definitive treatment was chemoradiation in 76.5% and laryngectomy in 23.5%. Change in primary tumor (OR = 5.78, p < 0.001) and N-classification (OR = 1.64, p = 0.003) predicted SR (AUC 0.847). Change in tumor volume (HR = 0.58, p < 0.001) predicted LFS (c-index 0.724). N-classification (HR = 1.48, p = 0.04) and pre-chemotherapy tumor volume (HR = 1.30, p = 0.174) predicted OS (c-index 0.552).

conclusionsImaging offers a non-invasive opportunity to evaluate response to induction chemotherapy, complementary to surgeon assessment. Further evaluation of approaches to bioselection that optimize generalizability of this paradigm are needed, and clinical trials utilizing imaging to predict outcomes including LFS are warranted.

Indexed as

Bioselection imagingChemoradiationLaryngectomyLocally advanced laryngeal cancer

Identifiers

PMID35024462
PMCPMC8728046
OpenAlexW4200301823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.